Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMMX |
---|---|---|
09:32 ET | 1475 | 1.585 |
09:39 ET | 200 | 1.57 |
09:43 ET | 100 | 1.55 |
09:45 ET | 2200 | 1.55 |
09:52 ET | 990 | 1.541 |
09:56 ET | 100 | 1.55 |
10:03 ET | 300 | 1.55 |
10:06 ET | 100 | 1.54 |
10:19 ET | 500 | 1.56 |
10:21 ET | 300 | 1.56 |
10:24 ET | 2232 | 1.56 |
10:33 ET | 100 | 1.55 |
10:37 ET | 1477 | 1.5699 |
10:44 ET | 600 | 1.57 |
10:48 ET | 600 | 1.55 |
10:50 ET | 1450 | 1.5796 |
11:00 ET | 1250 | 1.57 |
11:04 ET | 100 | 1.58 |
11:09 ET | 2200 | 1.56 |
11:20 ET | 330 | 1.58 |
11:27 ET | 2700 | 1.58 |
11:31 ET | 100 | 1.562 |
12:00 ET | 300 | 1.59 |
12:05 ET | 500 | 1.56 |
12:20 ET | 100 | 1.55 |
12:30 ET | 1000 | 1.578 |
01:01 ET | 100 | 1.55 |
01:19 ET | 683 | 1.58 |
01:21 ET | 400 | 1.5627 |
01:26 ET | 200 | 1.57 |
01:42 ET | 654 | 1.58 |
01:46 ET | 4279 | 1.57 |
02:09 ET | 127 | 1.565 |
02:15 ET | 639 | 1.565 |
02:20 ET | 1282 | 1.57 |
02:22 ET | 3300 | 1.56 |
02:51 ET | 100 | 1.57 |
03:05 ET | 1465 | 1.56 |
03:25 ET | 100 | 1.55 |
03:45 ET | 100 | 1.56 |
03:50 ET | 100 | 1.55 |
03:56 ET | 100 | 1.55 |
03:57 ET | 557 | 1.56 |
03:59 ET | 700 | 1.56 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immix Biopharma Inc | 51.1M | -1.9x | --- |
Passage Bio Inc | 49.8M | -0.5x | --- |
IO Biotech Inc | 49.5M | -0.7x | --- |
Vicapsys Life Sciences Inc | 48.4M | -46.1x | --- |
Allakos Inc | 53.7M | -0.3x | --- |
Anebulo Pharmaceuticals Inc | 53.9M | -5.6x | --- |
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $0.82 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.